Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Trisomy 8 in pediatric acute myeloid leukemia: A NOPHO-AML study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Blocking protein quality control to counter hereditary cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Novel fusion genes and chimeric transcripts in ependymal tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Response to: Patient-centred medical education: A proposed definition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Anne Cathrine Lund Laursen
  • Julie Damgaard Sandahl
  • Eigil Kjeldsen
  • Jonas Abrahamsson
  • Peter Asdahl
  • Shau-Yin Ha
  • Jesper Heldrup
  • Kirsi Jahnukainen
  • Ólafur G Jónsson
  • Birgitte Lausen
  • Josefine Palle
  • Bernward Zeller
  • Erik Forestier
  • Henrik Hasle
Vis graf over relationer

Trisomy 8 (+8) is a common cytogenetic aberration in acute myeloid leukemia (AML); however, the impact of +8 in pediatric AML is largely unknown. We retrospectively investigated 609 patients from the NOPHO-AML database to determine the clinical and cytogenetic characteristics of +8 in pediatric AML and to investigate its prognostic impact. Complete cytogenetic data were available in 596 patients (98%) aged 0-18 years, diagnosed from 1993 to 2012, and treated according to the NOPHO-AML 1993 and 2004 protocols in the Nordic countries and Hong Kong. We identified 86 patients (14%) with +8. Trisomy 8 was combined with other cytogenetic aberrations in 68 patients (11%) (+8 other) and in 18 patients (3%), it was the sole abnormality (+8 alone). Trisomy 8 was associated with FAB M5 (36%) but otherwise clinically comparable with non-trisomy 8 patients. Trisomy 8 was favorable in patients of young age and with t(9;11). Trisomy 8 alone was associated with older age (median age 10.1 years), FAB M2 (33%), and FLT3-ITD mutations (58%). The 5-year event-free survival for patients with +8 alone was 50% and 5-year overall survival was 75%. In conclusion, +8 is one of the most common cytogenetic aberrations in pediatric AML. Trisomy 8 positive AML is a heterogeneous group and the majority of cases have additional cytogenetic aberrations. Patients with +8 alone differed from patients with +8 other and were associated with older age, FAB M2, and FLT3-ITD aberrations. There were no differences in survival despite the more frequent occurrence of FLT3-ITD in +8 alone. © 2016 Wiley Periodicals, Inc.

OriginalsprogEngelsk
TidsskriftGenes Chromosomes and Cancer
Vol/bind55
Udgave nummer9
Sider (fra-til)719-26
Antal sider8
ISSN1045-2257
DOI
StatusUdgivet - sep. 2016

ID: 49871986